By Mill Chart
Last update: Feb 26, 2024
Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is suited for quality investing. Investors should of course do their own research, but we spotted NOVO-NORDISK A/S-SPONS ADR showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.
Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.
Taking everything into account, NVO scores 7 out of 10 in our fundamental rating. NVO was compared to 202 industry peers in the Pharmaceuticals industry. NVO scores excellent points on both the profitability and health parts. This is a solid base for a good stock. NVO is not priced too expensively while it is growing strongly. Keep and eye on this one! NVO also has an excellent dividend rating. With these ratings, NVO could be worth investigating further for dividend and growth and quality investing!.
Check the latest full fundamental report of NVO for a complete fundamental analysis.
More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (4/24/2024, 7:20:06 PM)
After market: 125 -1.16 (-0.92%)126.16
-2.48 (-1.93%)
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.
Lilly recently announced news that could solve a big problem.
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
These two pharma stocks have followed distinct paths of late. Which is the better investment?
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.
It's not only spending its capital on developing new drugs.
It's not only spending its capital on developing new drugs.
Creators say the rules are unfair and harmful to their businesses
These stocks probably won't be getting much cheaper.
Low risk and high-reward potential? These stocks could offer both.
Low risk and high-reward potential? These stocks could offer both.